Once-daily single-inhaler triple versus dual therapy in patients with COPD

New England Journal of Medicine

Volumn 378, Issue 18, 2018, Pages 1671-1680

  Lipson, David A ^a,b   Barnhart, Frank ^b   Brealey, Noushin ^c   Brooks, Jean ^b   Criner, Gerard J ^a   Day, Nicola C ^c   Dransfield, Mark T ^g   Halpin, David M G ^d   Han, MeiLan K ^h   Elaine Jones, C ^b   Kilbride, Sally ^c   Lange, Peter ^i,j   Lomas, David A ^e   Martinez, Fernando J ^k   Singh, Dave ^f   Tabberer, Maggie ^c   Wise, Robert A ^a   Pascoe, Steven J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k WEILL CORNELL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE PLUS UMECLIDINIUM PLUS VILANTEROL; FLUTICASONE FUROATE PLUS VILANTEROL; UMECLIDINIUM PLUS VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; FLUTICASONE FUROATE; GLUCOCORTICOID; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; UMECLIDINIUM; VILANTEROL;

AGED; ANTICHOLINERGIC SYNDROME; ARTICLE; ASTHMA; BODY MASS; BRAIN HEMORRHAGE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; URINE RETENTION; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; DYSPNEA; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DYSPNEA; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINUCLIDINES;

EID: 85046617345     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1713901     Document Type: Article

References (19)

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med 2017;195:557-82.
2. Pocket guide to COPD diagnosis, management, and prevention: a guide for health care professionals. Global Initiative for Obstructive Lung Disease, 2017 (http://goldcopd.org/wp-content/uploads/2016/12/ wms-GOLD-2017-Pocket-Guide.pdf).
3. Cazzola M, Andò F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007;20:556-61.
4. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/ salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012;106:91-101.
5. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012;106:382-9.
6. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budeso-nide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50.
7. Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal AA. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res 2012;13:15.
8. Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012;141:81-6.
9. Aaron SD, Vandemheen KL, Fergus-son D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
10. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-73.
11. Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/ vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med 2015;109:1155-63.
12. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389:1919-29.
13. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:438-46.
14. Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis 2016;12:73-83.
15. Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One 2014;9(9):e105296.
16. Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J 2016; 48:320-30.
17. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34.
18. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387: 1817-26.
19. Rotenstein LS, Huckman RS, Wagle NW. Making patients and doctors happier - the potential of patient-reported outcomes. N Engl J Med 2017;377:1309-12.